Publication

Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes

Vehof, J., Burger, H., Wilffert, B., Al Hadithy, A., Alizadeh, B. Z., Snieder, H. & GROUP Investigators, Sep-2012, In : European Neuropsychopharmacology. 22, 9, p. 625-631 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Vehof, J., Burger, H., Wilffert, B., Al Hadithy, A., Alizadeh, B. Z., Snieder, H., & GROUP Investigators (2012). Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes. European Neuropsychopharmacology, 22(9), 625-631. https://doi.org/10.1016/j.euroneuro.2012.01.006

Author

Vehof, Jelle ; Burger, Huibert ; Wilffert, Bob ; Al Hadithy, Asmar ; Alizadeh, Behrooz Z. ; Snieder, Harold ; GROUP Investigators. / Clinical response to antipsychotic drug treatment : Association study of polymorphisms in six candidate genes. In: European Neuropsychopharmacology. 2012 ; Vol. 22, No. 9. pp. 625-631.

Harvard

Vehof, J, Burger, H, Wilffert, B, Al Hadithy, A, Alizadeh, BZ, Snieder, H & GROUP Investigators 2012, 'Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes' European Neuropsychopharmacology, vol. 22, no. 9, pp. 625-631. https://doi.org/10.1016/j.euroneuro.2012.01.006

Standard

Clinical response to antipsychotic drug treatment : Association study of polymorphisms in six candidate genes. / Vehof, Jelle; Burger, Huibert; Wilffert, Bob; Al Hadithy, Asmar; Alizadeh, Behrooz Z.; Snieder, Harold; GROUP Investigators.

In: European Neuropsychopharmacology, Vol. 22, No. 9, 09.2012, p. 625-631.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh BZ, Snieder H et al. Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes. European Neuropsychopharmacology. 2012 Sep;22(9):625-631. https://doi.org/10.1016/j.euroneuro.2012.01.006


BibTeX

@article{2f6654eaa768418f8b8eaec926465681,
title = "Clinical response to antipsychotic drug treatment: Association study of polymorphisms in six candidate genes",
abstract = "Pharmacogenetic studies have demonstrated significant associations between several candidate genes (DRD2, DRD3, 5HTR2A and 5HTR2C, COMT and MTHFR) and antipsychotic drug response. The present study investigates the effect of nine polymorphisms in these genes for an association with antipsychotic treatment response. 329 Caucasian patients with a non-affective psychotic disorder using antipsychotics were included. All patients participated in the longitudinal GROUP-study in The Netherlands. We genotyped 9 SNPs in 6 candidate genes (DRD2: Taql_A, -141C; DRD3: Ser9Gly; HTR2A: 102-T/C, His452Tyr; HTR2C: Cys23Ser; COMT: Val158Met; MTHFR: 677-C/T) using standard protocols. Polymorphisms were based on previous studies showing associations with positive symptoms treatment response. The Clinical Global Impression Improvement (CGI-I) scale was used to assess improvement in positive psychotic symptoms since the start of current antipsychotic treatment. Ordinal regression was used for association analyses. Ninety percent of the patients used second generation antipsychotics, with olanzapine (28{\%}) and risperidone (29{\%}) being the most prescribed drugs. Ser9Gly of the dopamine D3 receptor gene (P value 0.034) and 677-C/T of MTHFR (P value 0.019) were tested statistically significant. Gly-carriers and T-carriers, respectively, showed more clinical improvement on the CGI-I. The other polymorphisms did not show a statistically significant association (P values>0.10). In conclusion, we replicated two out of nine of the previously reported associations between polymorphisms and treatment response. The direction and magnitude of the associations presented here in DRD3 (Ser9Gly) and MTHFR (677-C/T) are in line with previous association studies in Caucasian patients. These polymorphisms may be of value for predicting clinical response. (C) 2012 Elsevier B.V. and ECNP. All rights reserved.",
keywords = "Antipsychotics, Response, Schizophrenia, Polymorphism, Pharmacogenetics, Dopamine, Serotonin, DOPAMINE D-3 RECEPTOR, CLOZAPINE RESPONSE, 5-HT2A RECEPTOR, SCHIZOPHRENIA-PATIENTS, METHYLENETETRAHYDROFOLATE REDUCTASE, 1ST-EPISODE SCHIZOPHRENIA, HEALTHY-VOLUNTEERS, ALLELIC VARIATION, A1 ALLELE, PROMOTER",
author = "Jelle Vehof and Huibert Burger and Bob Wilffert and {Al Hadithy}, Asmar and Alizadeh, {Behrooz Z.} and Harold Snieder and {GROUP Investigators}",
note = "Copyright {\circledC} 2012 Elsevier B.V. All rights reserved.",
year = "2012",
month = "9",
doi = "10.1016/j.euroneuro.2012.01.006",
language = "English",
volume = "22",
pages = "625--631",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "ELSEVIER SCIENCE BV",
number = "9",

}

RIS

TY - JOUR

T1 - Clinical response to antipsychotic drug treatment

T2 - Association study of polymorphisms in six candidate genes

AU - Vehof, Jelle

AU - Burger, Huibert

AU - Wilffert, Bob

AU - Al Hadithy, Asmar

AU - Alizadeh, Behrooz Z.

AU - Snieder, Harold

AU - GROUP Investigators

N1 - Copyright © 2012 Elsevier B.V. All rights reserved.

PY - 2012/9

Y1 - 2012/9

N2 - Pharmacogenetic studies have demonstrated significant associations between several candidate genes (DRD2, DRD3, 5HTR2A and 5HTR2C, COMT and MTHFR) and antipsychotic drug response. The present study investigates the effect of nine polymorphisms in these genes for an association with antipsychotic treatment response. 329 Caucasian patients with a non-affective psychotic disorder using antipsychotics were included. All patients participated in the longitudinal GROUP-study in The Netherlands. We genotyped 9 SNPs in 6 candidate genes (DRD2: Taql_A, -141C; DRD3: Ser9Gly; HTR2A: 102-T/C, His452Tyr; HTR2C: Cys23Ser; COMT: Val158Met; MTHFR: 677-C/T) using standard protocols. Polymorphisms were based on previous studies showing associations with positive symptoms treatment response. The Clinical Global Impression Improvement (CGI-I) scale was used to assess improvement in positive psychotic symptoms since the start of current antipsychotic treatment. Ordinal regression was used for association analyses. Ninety percent of the patients used second generation antipsychotics, with olanzapine (28%) and risperidone (29%) being the most prescribed drugs. Ser9Gly of the dopamine D3 receptor gene (P value 0.034) and 677-C/T of MTHFR (P value 0.019) were tested statistically significant. Gly-carriers and T-carriers, respectively, showed more clinical improvement on the CGI-I. The other polymorphisms did not show a statistically significant association (P values>0.10). In conclusion, we replicated two out of nine of the previously reported associations between polymorphisms and treatment response. The direction and magnitude of the associations presented here in DRD3 (Ser9Gly) and MTHFR (677-C/T) are in line with previous association studies in Caucasian patients. These polymorphisms may be of value for predicting clinical response. (C) 2012 Elsevier B.V. and ECNP. All rights reserved.

AB - Pharmacogenetic studies have demonstrated significant associations between several candidate genes (DRD2, DRD3, 5HTR2A and 5HTR2C, COMT and MTHFR) and antipsychotic drug response. The present study investigates the effect of nine polymorphisms in these genes for an association with antipsychotic treatment response. 329 Caucasian patients with a non-affective psychotic disorder using antipsychotics were included. All patients participated in the longitudinal GROUP-study in The Netherlands. We genotyped 9 SNPs in 6 candidate genes (DRD2: Taql_A, -141C; DRD3: Ser9Gly; HTR2A: 102-T/C, His452Tyr; HTR2C: Cys23Ser; COMT: Val158Met; MTHFR: 677-C/T) using standard protocols. Polymorphisms were based on previous studies showing associations with positive symptoms treatment response. The Clinical Global Impression Improvement (CGI-I) scale was used to assess improvement in positive psychotic symptoms since the start of current antipsychotic treatment. Ordinal regression was used for association analyses. Ninety percent of the patients used second generation antipsychotics, with olanzapine (28%) and risperidone (29%) being the most prescribed drugs. Ser9Gly of the dopamine D3 receptor gene (P value 0.034) and 677-C/T of MTHFR (P value 0.019) were tested statistically significant. Gly-carriers and T-carriers, respectively, showed more clinical improvement on the CGI-I. The other polymorphisms did not show a statistically significant association (P values>0.10). In conclusion, we replicated two out of nine of the previously reported associations between polymorphisms and treatment response. The direction and magnitude of the associations presented here in DRD3 (Ser9Gly) and MTHFR (677-C/T) are in line with previous association studies in Caucasian patients. These polymorphisms may be of value for predicting clinical response. (C) 2012 Elsevier B.V. and ECNP. All rights reserved.

KW - Antipsychotics

KW - Response

KW - Schizophrenia

KW - Polymorphism

KW - Pharmacogenetics

KW - Dopamine

KW - Serotonin

KW - DOPAMINE D-3 RECEPTOR

KW - CLOZAPINE RESPONSE

KW - 5-HT2A RECEPTOR

KW - SCHIZOPHRENIA-PATIENTS

KW - METHYLENETETRAHYDROFOLATE REDUCTASE

KW - 1ST-EPISODE SCHIZOPHRENIA

KW - HEALTHY-VOLUNTEERS

KW - ALLELIC VARIATION

KW - A1 ALLELE

KW - PROMOTER

U2 - 10.1016/j.euroneuro.2012.01.006

DO - 10.1016/j.euroneuro.2012.01.006

M3 - Article

VL - 22

SP - 625

EP - 631

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 9

ER -

ID: 5693609